# Clarity Pharmaceuticals Type: Company (CU6) Source: GetYourBrief — https://getyourbrief.com/entity/clarity-pharmaceuticals Canonical HTML page: https://getyourbrief.com/entity/clarity-pharmaceuticals ## Timeline - **2027**: Phase III Milestones — Anticipated data readouts for TCT imaging agents supported by Cu-64 supply. - **2026-Q4**: Supply Chain Integration — Integration of Theragenics' output into Clarity's clinical trial logistics. - **2026-Q3**: Production Ramp-up — Expected commencement of large-scale isotope production for late-stage clinical trials. - **2026-Q2**: Process Integration — Technical teams begin integrating manufacturing protocols and quality control standards. - **2026-03-25**: Agreement Signed — Clarity and Theragenics formalize the large-scale manufacturing supply deal for Cu-64. - **2026-03-25**: Supply Agreement Signed — Clarity and Theragenics formalize large-scale Cu-64 manufacturing partnership. - **2026-02-24**: Reporting Season Pressure — Difficult February reports for CSL and Sonic Healthcare extend index declines. - **2026-02-15**: Anteris Funding — Anteris Technologies raises approximately $440 million for heart valve technology. - **2026-01-31**: Nasdaq Biotech Peak — The index records a 30% annual gain, diverging from broader tech markets. - **2025-12-31**: Record Funding Year — Clarity ($200m) and Mesoblast ($260m) complete significant capital raises. - **2025-01-01**: ASX Healthcare Slump — The sector begins a calendar year decline of 25% led by major heavyweights. ## Recent coverage (6 stories, network-wide) ### Clarity Secures Large-Scale Cu-64 Supply Agreement with Theragenics 2026-03-25 18:09:08 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 Clarity Pharmaceuticals has signed a major manufacturing supply agreement with Theragenics to secure large-scale production of copper-64. This partnership bolsters the supply chain for Clarity’s Targeted Copper Theranostics platform as it moves toward late-stage clinical trials. Full story: https://getbiobrief.com/story/clarity-theragenics-copper-64-supply-agreement ### Clarity Pharmaceuticals Secures Scalable Cu-64 Supply via Theragenics Deal 2026-03-25 18:09:03 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Clarity Pharmaceuticals has entered into a multi-year manufacturing supply agreement with Theragenics for the production of copper-64 (Cu-64). This partnership secures a reliable, large-scale supply of the isotope to support Clarity's clinical trials and future commercialization of its Targeted Copper Theranostics platform. Full story: https://gethealthbrief.com/story/clarity-theragenics-cu64-supply-deal ### Clarity and Theragenics Ink Major Copper-64 Manufacturing Supply Deal 2026-03-25 18:03:53 · Sector: supply · Sentiment: Positive · Impact: 6/10 · Sources: 2 Clarity Pharmaceuticals has secured a large-scale manufacturing supply agreement with Theragenics for the production of copper-64. This strategic partnership addresses critical supply chain bottlenecks for radiopharmaceuticals, ensuring a reliable flow of isotopes for Clarity’s diagnostic and therapeutic clinical trials. Full story: https://getsupplybrief.com/story/clarity-theragenics-copper-64-manufacturing-agreement ### Biotech’s Two-Speed Divergence: Innovation Thrives Amid Regulatory Headwinds 2026-02-25 00:13:27 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 5 The global healthcare sector is splitting into a 'two-speed' market as regulatory uncertainty under the Trump administration pressures established giants while innovative biotechs find significant capital. Despite a 25% decline in the ASX 200 healthcare index, smaller players are leveraging AI and record-setting capital raises to navigate a complex FDA landscape. Full story: https://getfinancebrief.com/story/biotech-two-speed-market-regulatory-analysis ### Biotech’s Two-Speed Market: Innovation Defies Regulatory Headwinds 2026-02-25 00:12:53 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 5 The global biotech sector has diverged into a 'two-speed' market, where innovative drug discovery and device firms are outperforming established healthcare heavyweights. Despite regulatory uncertainty under the Trump administration and a 25% decline in the ASX 200 healthcare sector, the Nasdaq Biotech Index has surged 30%, supported by record-breaking capital raises. Full story: https://getbiobrief.com/story/biotech-two-speed-market-analysis-2026 ### Biotech’s Two-Speed Recovery: Mid-Caps Surge Amid Large-Cap Stagnation 2026-02-25 00:08:45 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 5 The global healthcare sector is bifurcating as mid-cap biotech innovators outperform established heavyweights despite regulatory headwinds from the Trump administration. While the ASX 200 healthcare index fell 25% in 2025, a surge in capital raising and AI integration is fueling a resilient 'engine room' of drug discovery and device innovation. Full story: https://gethealthbrief.com/story/biotech-long-game-two-speed-market-2026 --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.